In conclusion, our results indicate that the <i>ERCC1</i> rs3212986 and the <i>ERCC2/XPD</i> rs1799793 could be used as surrogate markers for a better stratification of EC patients with advanced resectable tumor.
Several researchers have investigated the relationship between ERCC2 rs13181 and rs1799793 polymorphisms and chemotherapy efficacy in terms of tumour response and prognosis in gastric patients.
Although two SNPs in BRCA2 (rs144848, rs1801406) and two SNPs in ERCC2 (rs1799793, rs13181) showed stronger associations with high Gleason score or advanced-stage tumors when comparing homozygous men carrying the minor versus major allele, results were not statistically significantly different between clinically aggressive and non-aggressive tumors.
However, ERCC2 K751Q polymorphism was associated with an increased risk for non-cardial neoplasm [odds ratio (OR) = 1.78; 95% confidence interval (CI) 1.02-3.12], being ERCC2 K751Q and D312N polymorphisms associated with the diffuse type.